

New Data at ASH 2022 Bolster Servier's Leadership in Hematology Research

- **Real-world analysis findings highlight overall survival benefit in adolescent and young adult (AYA) newly-diagnosed acute lymphoblastic leukemia (ALL) patients treated with pediatric-inspired regimens (PIR) versus non-pediatric-inspired regimens**
- **Additional data in acute myeloid leukemia (AML) continue to reinforce the potential of IDH mutation inhibitors in the treatment of difficult-to-treat cancers**

BOSTON, November 3, 2022 – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will present new data in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10–13, 2022. These latest data add to the growing body of evidence from Servier's expanding oncology portfolio and underscore its commitment to finding innovative solutions to meet high unmet medical needs.

The research to be presented includes new insights on Servier's marketed therapies, as well as findings from a real-world analysis comparing overall survival among adolescent and young adults (AYA) with newly-diagnosed acute lymphoblastic leukemia (ALL) treated with pediatric-inspired regimens (including an asparaginase treatment) versus non-pediatric-inspired regimens.

"While pediatric-inspired regimens containing asparaginase have been the backbone of effective therapy for children and teenagers with most types of acute lymphoblastic leukemia, their use in young adults remains inconsistent across adult centers," said David R. Freyer, DO, MS, study co-author, Director of Survivorship & Supportive Care at Children's Hospital Los Angeles, and Co-Director of the AYA Cancer Program at the USC Norris Comprehensive Care Center. "I look forward to presenting our real-world analyses on the potential benefit of pediatric-inspired regimens for young adults with newly-diagnosed acute lymphoblastic leukemia to further our understanding of their impact on survival and survivorship."

"Five years after making our strategic commitment to the fight against cancer, the ASH conference allows us to highlight the progress made by the Group, our teams and our partners in developing targeted therapeutic solutions to treat patients with hard-to-treat cancer," said Claude Bertrand, Executive Vice President Research and Development of the Servier Group. "As a result of innovative and open research, as well as significant and continuous investment, Servier now has 20 oncology

projects in clinical development and 17 research projects¹ in cancers that meet a strong unmet medical need for patients.”

Servier abstracts being presented at ASH include:

Oral Presentation #223: Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML treated with IVO+AZA in the AGILE Study

- Date & Time: Saturday, December 10, 2022 at 2:00 pm
- Lead Author: Hartmut Döhner

Oral Presentation #906: Comparison of Overall Survival Among Adolescents and Young Adults (AYA) with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with Pediatric-Inspired or Non-Pediatric Inspired Regimens: A Real-World Analysis Using Claims Data

- Date & Time: Monday, December 12, 2022 at 4:00 pm
- Lead Author: Tarun Bhagnani

About Servier Pharmaceuticals

Servier Pharmaceuticals LLC is a commercial-stage company with a passion for innovation and improving the lives of patients, their families and caregivers. As a privately held company, Servier has the unique freedom to devote all of its time and energy towards patients who require our treatments, care and innovation in areas of unmet medical need.

As a leader in oncology, Servier is committed to finding solutions that will address today's challenges. The company's oncology portfolio includes innovative medicines designed to bring more life-saving treatments to a greater number of patients, across the entire spectrum of disease and in a variety of tumor types. Servier has significantly accelerated its investment in hard-to-treat cancers with more than 50% of its research and development dedicated to delivering significant advances in areas of high unmet need that may truly move the needle for our patients.

Servier believes co-creation is fundamental to driving innovation and is actively building alliances, acquisitions, licensing deals and partnerships that bring solutions and accelerate access to therapies. With the company's commercial expertise, global reach, scientific expertise and commitment to clinical excellence, Servier Pharmaceuticals is dedicated to bringing the promise of tomorrow to the patients that we serve.

For more information: www.servier.us

About Servier

Founded to serve health, Servier is a global group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,800 employees of the Group are committed to this shared vocation, source of inspiration every day.

As a world leader in cardiology, Servier's ambition is to become a renowned, focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 50% of its R&D budget to developing targeted and innovative therapies in oncology.

Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

¹ Data as of October 2022

To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.

In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.

Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €4.7 billion in 2021.

For more information on the new Group website: servier.com

Press contacts

Servier Pharmaceuticals (U.S.)
Julia Ferreira
julia.ferreira@servier.com

Servier Group (France and worldwide)
Sonia Marques
presse@servier.com
+33 (0)1 55 72 40 21 / + 33 (0)7 84 28 76 13

